
    
      Attention-Deficit/Hyperactivity Disorder (ADHD) is a psychiatric disorder characterized by 3
      main symptoms: inattention, hyperactivity and impulsivity. This study will evaluate the
      long-term safety of SPD485 in the symptomatic treatment of children aged 6-12 diagnosed with
      ADHD
    
  